Value Assessment Vexes Pharma As China Costs Soar, Prices Fall
Executive Summary
Traditionally a low-cost manufacturing haven, China has seen pharma R&D costs increase rapidly although prices for pharmaceuticals have not gone up, forcing officials and executives to explore value assessment and market access approaches in a toughening environment.
You may also be interested in...
Trade War Expansion? STAR Board Aims To Keep Lucrative China Biotech IPOs At Home
China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ChipScreen and marking a new rival to similar bourses in the US and Hong Kong. But some are cautioning that local regulators and investors will need to step up if the so-called China Nasdaq is to gain traction.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.